Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

NHS Accelerated Access Collaborative updated Rapid Uptake Products program for 2020/21

In November 2020, NHS Accelerated Access Collaborative updated the Rapid Uptake Products (RUP) program for 2020/21.

RUP program has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities but has lower than expected uptake to date. The Pathway Transformation Fund (PTF) is available to help NHS organizations use them more easily and quickly. The 2020/21 program builds on the successes of the 2019/20 RUPs program, with themes selected via an open, staged selection process.

Three Rapid Uptake Products from the 2019/20 program will continue through 2020/21:

  • Placental growth factor (PIGF) based tests for rule out pre-eclampsia
  • HeartFlow FFRCT – an analysis which creates a 3D model of the coronary arteries to help diagnose patients with suspected coronary artery disease from coronary CT angiography
  • PCSK9 inhibitors – will continue as part of a wider Lipid Management workstream.

Four new products will be supported through the 2020/21 RUP Programme:

  • Lipid Management - a novel, NICE-approved clinical pathway that includes three medicines: high-intensity statins (HIST), ezetimibe, and PCSK9 inhibitors (continued from 2019/20)
  • Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma (products NIOX VERO and NObreath) - a method of diagnosing asthma by measuring FeNO in the breath of patients suspected of having asthma
  • Biologics for treating severe asthma - Reslizumab, Benralizumab, Mepolizumab, and Omalizumab
  • Licensed repurposed therapies for use in managing breast cancer risk in people with a family history - Tamoxifen

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts” and “Reimbursement Alerts” every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).